Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 7(2), 137–151 (2006).
  Medline CASGoogle Scholar
• 2 Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J. Clin. Psychiatry 62(11), 869–877 (2001).
  Medline CASGoogle Scholar
• 3 Preskorn S, Patroneva A, Silman H et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J. Clin. Psychopharmacol. 29(1), 39–43 (2009).
  MedlineGoogle Scholar
• 4 Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther. Drug Monit. 22(2), 202–208 (2000).
  Medline CASGoogle Scholar
• 5 Sangkuhl K, Stingl JC, Turpeinen M, Altman RB, Klein TE. PharmGKB summary: venlafaxine pathway. Pharmacogenet. Genomics 24(1), 62–72 (2014).
  Medline CASGoogle Scholar
• 6 Fogelman SM, Schmider J, Venkatakrishnan K et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20(5), 480–490 (1999).
  Medline CASGoogle Scholar
• 7 Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br. J. Clin. Pharmacol. 41(2), 149–156 (1996).
  Medline CASGoogle Scholar
• 8 Hicks JK, Bishop JR, Sangkuhl K et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin. Pharmacol. Ther. 98(2), 127–134 (2015).
  Medline CASGoogle Scholar
• 9 Marez D, Legrand M, Sabbagh N et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7(3), 193–202 (1997).
  Medline CASGoogle Scholar
• 10 CYP2D6 allele nomenclature. www.cypalleles.ki.se/cyp2d6.htm
  Google Scholar
• 11 CYP2C19 allele nomenclature. www.cypalleles.ki.se/cyp2c19.htm
  Google Scholar
• 12 Spina E, De Leon J. Clinical applications of CYP genotyping in psychiatry. J. Neural Transm. (Vienna) 122(1), 5–28 (2015).
  Medline CASGoogle Scholar
• 13 Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138(1), 103–141 (2013).
  Medline CASGoogle Scholar
• 14 Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 53(2), 111–122 (2002).
  Medline CASGoogle Scholar
• 15 Hicks JK, Sangkuhl K, Swen JJ et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin. Pharmacol. Ther. doi:10.1002/cpt.597 (2016) (Epub ahead of print).
  MedlineGoogle Scholar
• 16 Shams ME, Arneth B, Hiemke C et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J. Clin. Pharm. Ther. 31(5), 493–502 (2006).
  Medline CASGoogle Scholar
• 17 Rau T, Wohlleben G, Wuttke H et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants – a pilot study. Clin. Pharmacol. Ther. 75(5), 386–393 (2004).
  Medline CASGoogle Scholar
• 18 Grasmader K, Verwohlt PL, Rietschel M et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J. Clin. Pharmacol. 60(5), 329–336 (2004).
  MedlineGoogle Scholar
• 19 Van Der Weide J, Van Baalen-Benedek EH, Kootstra-Ros JE. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther. Drug Monit. 27(4), 478–483 (2005).
  Medline CASGoogle Scholar
• 20 Nichols AI, Lobello K, Guico-Pabia CJ, Paul J, Preskorn SH. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status. J. Clin. Psychopharmacol. 29(4), 383–386 (2009).
  Medline CASGoogle Scholar
• 21 Lobello KW, Preskorn SH, Guico-Pabia CJ et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J. Clin. Psychiatry 71(11), 1482–1487 (2010).
  Medline CASGoogle Scholar
• 22 Kawanishi C, Lundgren S, Agren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur. J. Clin. Pharmacol. 59(11), 803–807 (2004).
  Medline CASGoogle Scholar
• 23 Ng C, Sarris J, Singh A et al. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Hum. Psychopharmacol. 28(5), 516–522 (2013).
  Medline CASGoogle Scholar
• 24 Rolla R, Gramaglia C, Dalo V et al. An observational study of Venlafaxine and CYP2D6 in clinical practice. Clin. Lab. 60(2), 225–231 (2014).
  Medline CASGoogle Scholar
• 25 Corruble E, El Asmar K, Trabado S et al. Treating major depressive episodes with antidepressants can induce or worsen metabolic syndrome: results of the METADAP cohort. World Psychiatry 14(3), 366–367 (2015).
  MedlineGoogle Scholar
• 26 Colle R, De Larminat D, Rotenberg S et al. Pioglitazone could induce remission in major depression: a meta-analysis. Neuropsychiatr. Dis. Treat. 13, 9–16 (2017).
  Medline CASGoogle Scholar
• 27 Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23, 56–62 (1960).
  Medline CASGoogle Scholar
• 28 Coulbault L, Beaussier M, Verstuyft C et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol. Ther. 79(4), 316–324 (2006).
  Medline CASGoogle Scholar
• 29 Steen VM, Andreassen OA, Daly AK et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5(4), 215–223 (1995).
  Medline CASGoogle Scholar
• 30 Preskorn SH. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters. J. Psychiatr. Pract. 16(1), 46–49 (2010).
  MedlineGoogle Scholar
• 31 Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60(2), 284–295 (1997).
  Medline CASGoogle Scholar
• 32 Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226(2), 327–338 (1999).
  Medline CASGoogle Scholar
• 33 Sanchez-Iglesias S, Garcia-Solaesa V, Garcia-Berrocal B et al. Role of pharmacogenetics in improving the safety of psychiatric care by predicting the potential risks of mania in cyp2d6 poor metabolizers diagnosed with bipolar disorder. Medicine (Baltimore) 95(6), e2473 (2016).
  Medline CASGoogle Scholar
• 34 Pietarinen P, Tornio A, Niemi M. High frequency of CYP2D6 ultrarapid metabolizer genotype in the Finnish population. Basic Clin. Pharmacol. Toxicol. 119(3), 291–296 (2016).
  Medline CASGoogle Scholar
• 35 Bertilsson L, Alm C, De Las Carreras C, Widen J, Edman G, Schalling D. Debrisoquine hydroxylation polymorphism and personality. Lancet 1(8637), 555 (1989).
  Medline CASGoogle Scholar
• 36 Llerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 87(1), 23–28 (1993).
  Medline CASGoogle Scholar
• 37 Coccaro EF. Impulsive aggression and central serotonergic system function in humans: an example of a dimensional brain-behavior relationship. Int Clin. Psychopharmacol. 7(1), 3–12 (1992).
  Medline CASGoogle Scholar
• 38 Yu AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, Gonzalez FJ. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13(3), 173–181 (2003).
  Medline CASGoogle Scholar
• 39 Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin. Pharmacol. Ther. 83(2), 322–327 (2008).
  Medline CASGoogle Scholar
• 40 Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9(5), 442–473 (2004).
  Medline CASGoogle Scholar
• 41 Eap CB, Lessard E, Baumann P et al. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 13(1), 39–47 (2003).
  Medline CASGoogle Scholar
• 42 Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur. J. Clin. Pharmacol. 56(2), 175–180 (2000).
  Medline CASGoogle Scholar
• 43 Nassan M, Nicholson WT, Elliott MA, Rohrer Vitek CR, Black JL, Frye MA. Pharmacokinetic pharmacogenetic prescribing guidelines for antidepressants: a template for psychiatric precision medicine. Mayo Clin. Proc. 91(7), 897–907 (2016).
  MedlineGoogle Scholar
• 44 Shah RR, Smith RL. Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br. J. Clin. Pharmacol. 79(2), 222–240 (2015).
  MedlineGoogle Scholar
• 45 Berm E, Kok R, Hak E, Wilffert B. Relation between CYP2D6 genotype, phenotype and therapeutic drug concentrations among nortriptyline and venlafaxine users in old age psychiatry. Pharmacopsychiatry 49(5), 186–190 (2016).
  Medline CASGoogle Scholar
• 46 Preskorn SH, Kane CP, Lobello K et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J. Clin. Psychiatry 74(6), 614–621 (2013).
  Medline CASGoogle Scholar
• 47 Chua EW, Foulds J, Miller AL, Kennedy MA. Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine. Pharmacogenet. Genomics 23(9), 494–497 (2013).
  Medline CASGoogle Scholar
• 48 Lamers F, Hoogendoorn AW, Smit JH et al. Sociodemographic and psychiatric determinants of attrition in The Netherlands Study of Depression and Anxiety (NESDA). Compr. Psychiatry 53(1), 63–70 (2012).
  MedlineGoogle Scholar
• 49 Vinetti M, Haufroid V, Capron A, Classen JF, Marchandise S, Hantson P. Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms. Clin. Toxicol. (Phila.) 49(9), 865–869 (2011).
  Medline CASGoogle Scholar
• 50 Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163(1), 28–40 (2006).
  MedlineGoogle Scholar
• 51 Berm EJ, Gout-Zwart JJ, Luttjeboer J, Wilffert B, Postma MJ. A model based cost-effectiveness analysis of routine genotyping for cyp2d6 among older, depressed inpatients starting nortriptyline pharmacotherapy. PLoS ONE 11(12), e0169065 (2016).
  MedlineGoogle Scholar